Level C· Early human research exploring benefitsProspective StudyPubMed

Glucocorticoid modulation of insulin signaling in human subcutaneous adipose tissue.

Gathercole LL., Bujalska IJ., Stewart PM., Tomlinson JW.

Prospective Study on Type 2 Diabetes, published in J Clin Endocrinol Metab (2007) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Clin Endocrinol Metab (2007)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
17711920
DOI
10.1210/jc.2007-1399

Abstract (original English)

Glucocorticoid (GC) excess is characterized by central obesity, insulin resistance, and in some cases, type 2 diabetes. However, the impact of GC upon insulin signaling in human adipose tissue has not been fully explored. We have examined the effect of GC upon insulin signaling in both human sc primary preadipocyte cultures and a novel human immortalized sc adipocyte cell line (Chub-S7) and contrasted this with observations in primary cultures of human skeletal muscle. This is an in vitro study characterizing the impact of GC upon insulin signaling in human tissues. Biopsy specimens were from healthy volunteers who gave their full and informed written consent. Combinations of treatments, including GC, RU38486, and wortmannin, were used. Insulin signaling cascade gene and protein expression and insulin-stimulated glucose uptake were determined. In human adipocytes, pretreatment with GC induced a dose-dependent [1.0 (control); 1.2 +/- 0.1 (50 nm); 2.2 +/- 0.2 (250 nm), P < 0.01 vs. control; 3.4 +/- 0.2 (1000 nm), P < 0.001 vs. control] and time-dependent [1.0 (1 h); 3.2 +/- 2.0 (6 h); 9.1 +/- 5.9 (24 h), P < 0.05 vs. 1 h; 4.5 +/- 2.2 (48 h)] increase in insulin-stimulated protein kinase B/akt phosphorylation. In addition, whereas insulin receptor substrate (IRS)-1 protein expression did not change, IRS-1 tyrosine phosphorylation increased. Furthermore, GC induced IRS-2 mRNA expre

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AdipocytesCell LineDose-Response Relationship, DrugGlucocorticoidsGlucoseHumansInsulinInsulin ResistanceLipid MetabolismMuscle Fibers, Skeletal

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research